Quark Pharmaceuticals Inc. Announces Completion Of Phase 2 Trial Evaluating QPI-1002 For Prevention Of Delayed Graft Function In Kidney Transplant Patients
7/1/2014 9:02:30 AM
FREMONT, Calif., July 1, 2014 (GLOBE NEWSWIRE) -- Quark Pharmaceuticals, Inc. today reported completion of a randomized, placebo-controlled multicenter Phase II trial of QPI-1002 for the prophylaxis of delayed graft function (DGF) in ESRD dialysis-dependent patients undergoing deceased donor kidney transplantation. The results of the trial will be presented at the 2014 World Transplant Conference in San Francisco, as an oral presentation in the late-breaking session on Monday, July 28, 2014. Novartis has an exclusive worldwide license option for the development and commercialization QPI-1002.
Help employers find you! Check out all the jobs and post your resume.
comments powered by